Answers are grounded in this paper and cite their sources.
Introduction: Understanding both patient and dermatology provider (DP) perspectives is critical to optimizing psoriasis (PsO) care. This study characterized treatment experiences, disease burden, quality-of-life impact, treatment goals, preferences, and unmet needs among Brazilian adults with psoriasis and dermatology providers actively treating psoriasis. Methods: A cross-sectional web-based survey conducted between October-November 2025 among Brazilian adults with PsO who were eligible for systemic therapy according to International Psoriasis Council guidelines and dermatology providers (DPs) who actively managed PsO patients. The Dermatology Life Quality Index (DLQI) was used to assess the impact of PsO on patients’ health related quality of life (HRQoL). Results: Responses were received from 251 adult patients and 100 dermatology providers. Patients had a mean age of 36 years, 65% were female, and 30% self-reported body surface area involvement ≥10%, including approximately 18% reporting disease duration over 7 years. Psoriatic arthritis (PsA) was reported by 26% of patients, while depression (32%) and hypertension (22%) were commonly reported comorbidities. The most affected body areas were the scalp (60%), arms (49%), hands (49%), and legs (40%). Pruritus was the most frequently reported symptom, affecting 88% of patients; among these, 86% experienced itch-related sleep disruption ≥3 nights per month, and 85% reported that itching interfered with their ability to focus on daily activities. PsO substantially affected patients’ quality of life: 82% of patients had a DLQI (range 0-30) score ≥6, reflecting at least moderate impact, and 62% had a score ≥11, indicating a very large or extremely large impact. Overall, patients attributed their PsO burden to multiple factors, most frequently skin symptoms (74%), PsO location (41%), lack of effective treatments (33%), impact on mental health (33%), and impact on social activities (28%). Patients reported currently using topical steroids (48%), nonsteroidal topicals (28%), oral treatments (38%), subcutaneous injection (14.3%), and intravenous (6%), while 11% were not receiving treatment (responses not mutually exclusive). The most frequently reported reasons for treatment discontinuation were limited effectiveness for oral treatments (53%) and side effects associated with injectables (50%). According to DPs, patients’ leading concerns about injectable treatments were dislike of needles (59%), discomfort with self-injection (47%), and cost or inadequate insurance coverage (46%).Oral treatment was the preferred treatment modality among both patients (61%) and DPs (53%), compared with topical (30% and 12%, respectively) and injectable therapies (10% and 33%, respectively). Nearly all patients currently receiving injectable therapy (98%) indicated willingness to switch to a safe and equally effective new oral therapy. Patients’ top treatment goals were reducing itch (72%), achieving clear skin (66%), and improving social well-being (37%). When selecting treatment, DPs prioritized treatment effectiveness (82%), long-term safety (67%) and potential side effects (51%) as the most important factors. Conclusion: PsO imposes a significant disease burden with profound impact on the HRQoL of Brazilian patients. There remains unmet need for oral PsO therapies that deliver high levels of skin clearance with a favorable safety profile, enabling patients and DPs to achieve optimal outcomes without compromising effectiveness, safety, or the preference for oral route of administration.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: